Control of a Mucosal Challenge and Prevention of AIDS by a Multiprotein DNA/MVA Vaccine-Reference-Cited by-同舟云学术

Control of a Mucosal Challenge and Prevention of AIDS by a Multiprotein DNA/MVA Vaccine

Published:2001-04-06 Issue:5514 Volume:292 Page:69-74
ISSN:0036-8075
Container-title:Science
language:en
Short-container-title:Science

Author:

Amara Rama Rao¹²,Villinger Francois³,Altman John D.²,Lydy Shari L.¹²,O'Neil Shawn P.¹²,Staprans Silvija I.⁴,Montefiori David C.⁵,Xu Yan¹,Herndon James G.¹,Wyatt Linda S.⁶,Candido Maria Angelito¹,Kozyr Natalia L.⁴,Earl Patricia L.⁶,Smith James M.¹²,Ma Hak-Ling¹⁷,Grimm Bennett D.³,Hulsey Michael L.²,Miller Joseph²,McClure Harold M.¹,McNicholl Janet M.⁷,Moss Bernard⁶,Robinson Harriet L.¹²

Affiliation:

1. Vaccine Research Center and Yerkes Regional Primate Research Center, Emory University, Atlanta, GA 30329, USA.

2. Vaccine Research Center and Department of Microbiology and Immunology of Emory University School of Medicine, Atlanta, GA 30322, USA.

3. Vaccine Research Center and Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA 30322, USA.

4. Vaccine Research Center and Department of Medicine, Division of Infectious Diseases of Emory University School of Medicine, Atlanta, GA 30322, USA.

5. Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA.

6. Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.

7. Division of AIDS, STD and TB Laboratory Research, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30330, USA.

Abstract

Heterologous prime/boost regimens have the potential for raising high levels of immune responses. Here we report that DNA priming followed by a recombinant modified vaccinia Ankara (rMVA) booster controlled a highly pathogenic immunodeficiency virus challenge in a rhesus macaque model. Both the DNA and rMVA components of the vaccine expressed multiple immunodeficiency virus proteins. Two DNA inoculations at 0 and 8 weeks and a single rMVA booster at 24 weeks effectively controlled an intrarectal challenge administered 7 months after the booster. These findings provide hope that a relatively simple multiprotein DNA/MVA vaccine can help to control the acquired immune deficiency syndrome epidemic.

Publisher

American Association for the Advancement of Science (AAAS)

Subject

Multidisciplinary

Reference34 articles.

1. Goulder P. J., et al., AIDS 13, S121 (1999).

2. Control of Viremia and Prevention of Clinical AIDS in Rhesus Monkeys by Cytokine-Augmented DNA Vaccination

3. Robinson H. L., et al., AIDS Rev. 2, 105 (2000).

4. Neutralizing antibody-independent containment of immunodeficiency virus challenges by DNA priming and recombinant pox virus booster immunizations

5. Karlsson G. B., et al., J. Virol. 71, 4218 (1997).

Cited by 66 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. High throughput analysis of B cell dynamics and neutralizing antibody development during immunization with a novel clade C HIV-1 envelope;PLOS Pathogens;2023-10-25

2. Intradermal but not intramuscular modified vaccinia Ankara immunizations protect against intravaginal tier2 simian-human immunodeficiency virus challenges in female macaques;Nature Communications;2023-08-08

3. Urgency and necessity of Epstein-Barr virus prophylactic vaccines;npj Vaccines;2022-12-09

4. Heat-inactivated modified vaccinia virus Ankara boosts Th1 cellular and humoral immunity as a vaccine adjuvant;npj Vaccines;2022-10-19

5. Limited impact of fingolimod treatment during the initial weeks of ART in SIV-infected rhesus macaques;Nature Communications;2022-08-27